TRIM33 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL359745	0.55	3/20
SCHEMBL327222	0.50	3/20
SCHEMBL210977	0.48	3/20
SCHEMBL73153	0.47	3/20
SCHEMBL93023	0.46	3/20
SCHEMBL146118	0.43	3/20
SCHEMBL111707	1.00	2/20
SCHEMBL112034	1.00	2/20
SCHEMBL190509	1.00	2/20
SCHEMBL268555	1.00	2/20
Salicyladehyde (SCHEMBL50021)	0.82	2/20
Salicyladehyde (SCHEMBL183269)	0.75	2/20
Cyclohexanone (SCHEMBL74298)	0.69	2/20
SCHEMBL110906	0.65	2/20
SCHEMBL110907	0.65	2/20
SCHEMBL272370	0.65	2/20
SCHEMBL272371	0.65	2/20
SCHEMBL284379	0.65	2/20
Cyclohexanone (SCHEMBL295059)	0.65	2/20
SCHEMBL343958	0.65	2/20

Clinical trials — most relevant to TRIM33 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study	PHASE3	COMPLETED
3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)	PHASE2	COMPLETED
Oral Nitrite for Older Heart Failure Patients	PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Neoadyuvant High-dose of Ifosfamide and Concurrent Radiotherapy in Soft Tissue Sarcoma	PHASE2	COMPLETED
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas	PHASE1	COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease	EARLY_PHASE1	RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Signaling Pathways Targeting Colorectal Cancer in Egypt	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
NLRP3 Inflammasome and Physical Therapy in ICU-Acquired Weakness	nan	RECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit	nan	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse	nan	ACTIVE_NOT_RECRUITING
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients	nan	UNKNOWN
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure	nan	COMPLETED
Using Mobile Technology to Improve Self-Regulation	nan	COMPLETED
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
The Role of Ectopic Fat and Heart Attack Risk in HIV	nan	RECRUITING
Myotubular and Centronuclear Myopathy Patient Registry	nan	RECRUITING
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Exploring Novel Biomarkers of ICU-AW in Mechanically Ventilated Children at the Molecular Level	nan	ENROLLING_BY_INVITATION
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract	nan	UNKNOWN
Family Blood Pressure Program - GenNet Network	nan	COMPLETED
Immune Cell Response to Stimuli	nan	RECRUITING
High-definition Surface Electromyography Markers for the Diagnosis of Sarcopenia	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TRIM33 binder may also engage these)

Protein	Name	Similarity
Q99PP7	—	1.000	Q99PP7 →
TRIM24	Transcription intermediary factor 1-alpha	0.999	landscape →
Q64127	—	0.997	Q64127 →
Q56R14	—	0.994	Q56R14 →
Q6E2N3	—	0.989	Q6E2N3 →
Q62925	—	0.988	Q62925 →
O70546	—	0.988	O70546 →
Q09YG9	—	0.987	Q09YG9 →
Q09YJ3	—	0.987	Q09YJ3 →
Q5XJV7	—	0.986	Q5XJV7 →
HIPK1	Homeodomain-interacting protein kinase 1	0.986	landscape →
Q9H694	—	0.986	Q9H694 →
Q2IBF8	—	0.986	Q2IBF8 →
Q07E15	—	0.985	Q07E15 →
Q96KQ4	—	0.985	Q96KQ4 →
Q7Z3K3	—	0.985	Q7Z3K3 →
O88907	—	0.984	O88907 →
Q09YI1	—	0.984	Q09YI1 →
MAP3K1	Mitogen-activated protein kinase kinase kinase 1	0.984	landscape →
KAT2B	Histone acetyltransferase KAT2B	0.984	landscape →
Q6EE22	—	0.984	Q6EE22 →
Q2IBE6	—	0.984	Q2IBE6 →
Q62318	—	0.984	Q62318 →
Q62415	—	0.983	Q62415 →
Q5U4T7	—	0.983	Q5U4T7 →
Q5IS44	—	0.983	Q5IS44 →
A1X157	—	0.983	A1X157 →
Q5IS89	—	0.983	Q5IS89 →
A0M8T5	—	0.983	A0M8T5 →
Q8C7R7	—	0.983	Q8C7R7 →